Omega-3: what the research currently supports

Long-chain omega-3 fatty acids (EPA and DHA) are among the most-studied food supplements in the world. The evidence base is large and partly settled, and notably more nuanced than older "fish oil prevents heart attacks" claims.

What the body needs#

EPA and DHA are essential fatty acids in the sense that the human body makes them inefficiently from plant-source alpha-linolenic acid (ALA). The reliable dietary source is oily fish (salmon, mackerel, sardines, herring, anchovies) or supplements.

The UK NHS recommends one portion of oily fish per week, which provides roughly 1–2 g of EPA + DHA averaged across the week.

Cardiovascular evidence#

The history here is informative.

Old evidence (1970s–2000s): Observational data and early RCTs (GISSI-Prevenzione 1999) supported the idea that fish oil reduces cardiovascular events. Public health and product messaging built on this.

Newer evidence (2010s): Large RCTs in modern populations on optimal medical therapy (statins, BP control) found smaller or null effects. VITAL (2018) — 25,000 adults, 5 years — found no reduction in major cardiovascular events with 1 g/day EPA+DHA.

The high-dose exception: REDUCE-IT (2018, NEJM) used 4 g/day of icosapent ethyl (a purified EPA) in adults with high cardiovascular risk and high triglycerides on statins. It showed significant reduction in major adverse cardiovascular events. STRENGTH (2020), using a mixed EPA/DHA preparation at similar dose, did not replicate the benefit.

The reasonable summary: typical-dose fish oil for primary prevention in well-treated adults doesn't appear to add much. High-dose purified EPA in specific clinical contexts may add real benefit.

Triglyceride lowering#

Both EPA and EPA/DHA combinations reliably lower triglycerides at doses of 2–4 g/day. This is one of the more reproducible effects in the supplement literature and is reflected in NICE guidance for severe hypertriglyceridaemia.

Cognition and mental health#

Depression. Multiple meta-analyses suggest EPA-predominant supplements may have modest adjunctive effects in major depression, particularly in trials using ≥1 g EPA/day. NICE has not adopted this as a first-line treatment.

Cognitive decline and dementia. Large RCTs (VITAL-Cog, others) have generally not shown protection against cognitive decline in cognitively normal older adults at typical doses.

Pregnancy and infant brain development. DHA in pregnancy and infancy has some supporting evidence; UK NHS guidance encourages oily fish intake in pregnancy.

Dose#

Most supplement bottles list "fish oil" total weight (e.g. 1,000 mg) rather than EPA + DHA content, which can be much lower. Check the label for actual EPA and DHA amounts.

• For general supplementation in adults without oily fish in their diet: 1–2 g/day total EPA + DHA is a reasonable target consistent with NHS dietary recommendations.
• For triglyceride lowering or specific clinical contexts: higher doses (2–4 g/day) are clinical decisions, often with prescription-strength preparations.

Quality concerns#

Fish oil supplements vary widely in oxidation status. Rancid oil has unpleasant aftertaste and may not deliver what the label promises. Look for:

• Third-party tested for oxidation (TOTOX value)
• Sustainable sourcing markers (MSC certification)
• Cold-stored, opaque packaging

Algae-derived omega-3 (vegan source of EPA/DHA) is increasingly available and chemically equivalent.

Practical position#

For people who don't eat oily fish, a modest omega-3 supplement is a reasonable nutritional gap-filler. For people eating 1–2 portions of oily fish per week, supplementation likely adds little. For specific clinical indications (high triglycerides, severe hypertriglyceridaemia), a clinician's input on prescription-strength preparation makes more sense than picking a supplement off a shelf.

The supplement isn't useless. It's also not the cardiovascular insurance policy older marketing implied.